Singapore markets close in 5 hours 23 minutes

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.13+0.22 (+2.78%)
At close: 04:00PM EST
8.14 +0.01 (+0.12%)
After hours: 07:53PM EST
Full screen
Trade prices are not sourced from all markets
Previous close7.91
Bid8.00 x 1800
Ask8.25 x 1000
Day's range7.93 - 8.26
52-week range5.42 - 18.73
Avg. volume5,140,850
Market cap1.283B
Beta (5Y monthly)0.12
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%

    Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.

  • Motley Fool

    Why Iovance Biotherapeutics Stock Soared 12% Higher Today

    Investors were more than cheered by a business update from cancer-focused biotech Iovance Biotherapeutics (NASDAQ: IOVA) on Monday. For Proleukin, an interleukin-2 molecule used to stimulate T-cell activity in the fight against cancer, Iovance is making an upfront payment of 166.7 million British pounds ($206.6 million). It is also on the hook for a 41.7 million pound ($51.7 million) milestone payment upon first approval of its leading pipeline therapy, advanced melanoma treatment Lifileucel, and what it described only as double-digit worldwide sales royalties derived from Proleukin.

  • Zacks

    Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug

    Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.